MBTPS1 and myeloid sarcoma: While modulating S1P signalling via the pharmacological approaches has shown beneficial outcomes on remyelination [18], fingolimod and its derivatives are only partially effective in a proportion of MS patients, primarily relapse-remitting forms of MS.